Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity
Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity
复制标题
DOI：
10.1300/j069v25n02_03
复制
发表时间：
2006-01-01
影响因子：
2.3
通讯作者：
Mauck, Kimberly
中科院分区：
文献类型：
--
作者：
Weaver, Michael F.;Hoffman, Heather J.;Mauck, Kimberly
研究表明，症状触发给药最适合治疗化学依赖病房没有其他疾病的患者的酒精戒断。在综合医院病房，停药可能会受到合并症的影响。一项临床试验旨在确定在一所大学医疗中心普通病房住院的患者中劳拉西泮的症状触发（ST）剂量和固定时间表（FS）剂量是否存在差异。护士使用修订后的临床研究所酒精戒断评估 (CIWA-Ar) 量表对 183 名受试者进行了评估。 ST 组的受试者根据 CIWA-Ar 评分接受劳拉西泮剂量。 FS 组的受试者接受预定的劳拉西泮治疗，并在 4 天内逐渐减量。对于普通内科住院患者，症状触发的酒精戒断剂量会导致劳拉西泮用量减少，前 2 天 CIWA-Ar 评分也有类似下降，但方案错误比例较高。
Studies show that symptom-triggered dosing is best for treatment of alcohol withdrawal in patients on chemical dependence wards without other illness. On general medical hospital wards, withdrawal may be affected by comorbid medical illness. A clinical trial was undertaken to determine whether there is a difference between symptom-triggered (ST) and fixed-schedule (FS) dosing of lorazepam in patients hospitalized on general medical wards at a university medical center. One hundred eighty-three subjects were assessed by their nurses with the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale. Subjects in the ST arm received lorazepam doses based on CIWA-Ar score. Subjects in the FS arm received scheduled lorazepam with tapering over 4 days. Symptom-triggered dosing for alcohol withdrawal for general medicine inpatients results in less lorazepam given with similar reduction in CIWA-Ar scores for the first 2 days, but a higher proportion of protocol errors.